DNMT3A and hematologic disorder: DNMT1 has been a focal point for mechanistic studies Involving decitabine and bortezomib in hematological malignancies, nevertheless mechanisms regarding DNMT3a and DNMT3b activity remain largely unclear upon treatment with these drugs [161].